WO2011087343A3 - Composition for treating cancer related to an hpv infection - Google Patents

Composition for treating cancer related to an hpv infection Download PDF

Info

Publication number
WO2011087343A3
WO2011087343A3 PCT/KR2011/000365 KR2011000365W WO2011087343A3 WO 2011087343 A3 WO2011087343 A3 WO 2011087343A3 KR 2011000365 W KR2011000365 W KR 2011000365W WO 2011087343 A3 WO2011087343 A3 WO 2011087343A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
present
infection
chemosensitizer
radiosensitizer
Prior art date
Application number
PCT/KR2011/000365
Other languages
French (fr)
Korean (ko)
Other versions
WO2011087343A2 (en
Inventor
신영기
정헌순
김영덕
Original Assignee
(주)이젠바이오텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)이젠바이오텍 filed Critical (주)이젠바이오텍
Publication of WO2011087343A2 publication Critical patent/WO2011087343A2/en
Publication of WO2011087343A3 publication Critical patent/WO2011087343A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a chemosensitizer or radiosensitizer for the treatment of cancer caused by a human papillomavirus (hereinafter referred to as HPV) infection. More particularly, the present invention relates to a chemosensitizer or radiosensitizer for treating cancer caused by a HPV infection, which contains, as an active ingredient, small interfering RNA, short hairpin RNA (shRNA) or antisense oligonucleotide (ASO) selected from a group consisting of nucleotide sequence numbers 1 to 10. The siRNA of the present invention has superior effects in treating cervical cancer when compared to cases in which therapy using HPV-specific siRNA, chemotherapy, or radiotherapy is performed alone, and increases the sensitivity of cervical cancer cells to radiation or anticancer agents to thereby achieve maximized apoptotic effects.
PCT/KR2011/000365 2010-01-18 2011-01-18 Composition for treating cancer related to an hpv infection WO2011087343A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0004311 2010-01-18
KR1020100004311A KR101197627B1 (en) 2010-01-18 2010-01-18 Composition for treatment of HPV-related cancers

Publications (2)

Publication Number Publication Date
WO2011087343A2 WO2011087343A2 (en) 2011-07-21
WO2011087343A3 true WO2011087343A3 (en) 2011-12-01

Family

ID=44304852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000365 WO2011087343A2 (en) 2010-01-18 2011-01-18 Composition for treating cancer related to an hpv infection

Country Status (2)

Country Link
KR (1) KR101197627B1 (en)
WO (1) WO2011087343A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520383B1 (en) * 2012-08-02 2015-05-15 에이비온 주식회사 Composition for Treating HPV-related Cancers
CN104324363A (en) * 2014-09-30 2015-02-04 苑振贵 Drug for treating cervical erosion and cervical cancer
KR20160133293A (en) * 2015-05-12 2016-11-22 에이비온 주식회사 Sensitizing composition for cancer comprising an agent inhibiting expression of oncogenes of HPV virus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100441202B1 (en) * 2001-12-11 2004-07-23 대한민국 Fertilized egg of mouse expressing HPV E6
KR20080040412A (en) * 2006-11-03 2008-05-08 재단법인서울대학교산학협력재단 Composition for treatment of cervix cancer
US7378099B2 (en) * 2002-10-03 2008-05-27 Wyeth Human papillomavirus polypeptides and immunogenic compositions
KR20080100353A (en) * 2006-02-01 2008-11-17 더 존스 홉킨스 유니버시티 Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6084090A (en) 1997-09-05 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus anti-sense oligonucleotides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100441202B1 (en) * 2001-12-11 2004-07-23 대한민국 Fertilized egg of mouse expressing HPV E6
US7378099B2 (en) * 2002-10-03 2008-05-27 Wyeth Human papillomavirus polypeptides and immunogenic compositions
KR20080100353A (en) * 2006-02-01 2008-11-17 더 존스 홉킨스 유니버시티 Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
KR20080040412A (en) * 2006-11-03 2008-05-08 재단법인서울대학교산학협력재단 Composition for treatment of cervix cancer

Also Published As

Publication number Publication date
KR101197627B1 (en) 2012-11-07
WO2011087343A2 (en) 2011-07-21
KR20110084650A (en) 2011-07-26

Similar Documents

Publication Publication Date Title
WO2014022739A3 (en) Modified rnai agents
MX2013009191A (en) Antisense oligonucleotides.
WO2018183808A9 (en) Antiviral therapeutic
WO2012149546A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
WO2009017803A3 (en) Antisense microrna and uses therefor
WO2013074974A3 (en) Modified rnai agents
EA201492148A1 (en) METHOD OF TREATMENT OF LITTLE-CELL LUNG CANCER
WO2012002760A3 (en) Method for treating and diagnosing cancer by using cell-derived microvesicles
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2010138806A8 (en) Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
WO2011059505A3 (en) Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
WO2005112636A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF PRIMATE POLYOMAVIRUS GENES
WO2008154482A3 (en) Sirna compositions and methods of use in treatment of ocular diseases
WO2009104051A3 (en) Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine
WO2011130458A3 (en) Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use
WO2011038933A3 (en) Anti-hsv antibody
WO2008045576A3 (en) Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
AU2009279857A8 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides
WO2012142313A8 (en) Micro-rna inhibitors and their uses in disease
MX2010006039A (en) Rna antagonist compounds for the modulation of pik3ca expression.
WO2021022888A9 (en) Aso targeting long-chain non-coding rna ddx11-as1, kit and application in treatment of liver cancer
MX2013010524A (en) Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer.
WO2011109422A3 (en) Compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11733130

Country of ref document: EP

Kind code of ref document: A2